Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Current Assets
Cash and cash equivalents	$ 14,032	$ 10,299
Marketable securities	11,125	32,754
Prepaid and other current assets	815	1,053
Total current assets	25,972	44,106
Property and equipment, net	100	165
Other assets	1,081	309
Total assets	27,153	44,580
Liabilities
Accounts payable	1,490	762
Accrued liabilities	4,486	4,857
Total current liabilities	5,976	5,619
Other long-term liabilities	624	1,507
Total liabilities	6,600	7,126
Commitments and Contingencies
Stockholders' Equity
Preferred stock; authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 0.001 share of common stock, $.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at December 31, 2019 and December 31, 2018, respectively	0	0
Common stock, $.001 par value, authorized 500,000,000 shares; issued and outstanding, 10,528,689 and 9,865,735 shares, at December 31, 2019 and December 31, 2018, respectively	11	10
Additional paid-in capital	438,911	436,433
Treasury stock, at cost; 11,080 shares at December 31, 2019 and December 31, 2018 respectively	(708)	(708)
Accumulated deficit	(417,400)	(397,977)
Accumulated other comprehensive income (loss)	2	(32)
Total Caladrius Biosciences, Inc. stockholders' equity	20,816	37,726
Noncontrolling interests	(263)	(272)
Total equity	20,553	37,454
Liabilities and Equity, Total	$ 27,153	$ 44,580